AIRS is down -11.37% at $3.04 during Monday’s regular session (3:16 PM ET), versus Friday’s close of $3.43. The selling extends post-Q2-earnings volatility: revenue fell to $42.9M from $44.01M, net loss widened, and FY26 revenue guidance was reaffirmed only at the lower end of $151M-$157M.
LFTO is down -9.07% to $19.65 during Monday regular trading, versus Friday's $21.61 close. The decline extends the stock's post-earnings slide despite Q2 revenue of $219.5M beating consensus and Q3/FY26 guidance topping estimates.
ODD fell -9.84% during Monday’s regular session to $11.82, versus Friday’s $13.11 close. No company-specific headline drove the move; selling continues the post-Q1 slide tied to the ad-algorithm dislocation that doubled customer acquisition costs and cut revenue -26%.
PICS is down -9.81% to $10.30 in regular Monday trading, versus Friday's close of $11.42. The decline occurred during market hours, not premarket or after-hours; shares were already off about -7.6% near midday and weakened further into the afternoon.
EMAT is trading down -11.63% at $2.68 on Monday, versus Friday’s close of $3.03, extending a premarket decline into the regular session. Q2 results were the main catalyst: revenue of $1.636M missed the $2.100M consensus, even though the -$0.02 EPS loss was narrower than the -$0.03 estimate.
UMAC is trading down -11.63% at $30.10 during Monday's regular session, retreating from Friday's close of $34.06. The decline follows Friday's +25% surge to a 52-week high after President Trump announced tariffs of up to 100% on imported drones and components, favoring U.S.-based UMAC.
BALY is trading down -28.45% to $10.01 in Monday's regular session versus Friday's close of $13.99. The selloff follows Friday night's 10-Q filing, which disclosed "substantial doubt" about going-concern status and expected non-compliance with liquidity and leverage covenants.
SPCX gained +5.89% during regular trading, rising to $148.25 from Friday's $140.00 close. The advance extends a rebound that carried shares back above the $135 IPO price after the August 6 lockup expiry failed to trigger heavy selling.
NWBO is the ticker for Northwest Biotherapeutics, Inc., a clinical-stage biotechnology company focused on personalized cancer immunotherapy. The company's lead candidate, DCVax-L, targets glioblastoma, an aggressive form of brain cancer, and has completed a Phase III clinical trial.
SPXS fell approximately 11.6% over the trailing 30 days, moving from a closing price of $26.98 to a latest price near $23.86, as the S&P 500 advanced. Over the trailing three-month period, the fund declined roughly 13.9% , extending a downward trend driven by broad large-cap equity strength.
PURR is up +5.99% to $7.08 in regular trading versus the previous session close of $6.68. The gain is occurring during market hours after shares gapped higher in the premarket.
Selected price target: $40, roughly 22% above the most recent close and just above the highest published analyst target near $39. Strongest bullish factors: accelerating revenue growth, a major second-quarter earnings beat, raised full-year guidance, improving profitability, and a cash-rich balance sheet.
United States Oil Fund, LP (USO) is a commodity-pool exchange-traded product, rather than a conventional equity exchange-traded fund (ETF), that seeks to track daily percentage changes in West Texas Intermediate (WTI) light, sweet crude oil through near-month New York Mercantile Exchange (NYMEX) futures. The fund's concentrated exposure to crude oil futures makes WTI price direction, the shape of the futures curve, and collateral yields the dominant drivers of ETF performance.
STUB is trading down -10.89% at $7.20 during Monday's regular session, extending its post-earnings slide. Pressure follows reports of a proposed class action over ticketing failures and delayed refunds.
Selected price target: $200 per share, roughly 15% above Reddit's recent trading range near $173–$178. Strongest bullish factors: better-than-expected second-quarter revenue and earnings, 91% gross margin, 50% average revenue per user growth, and S&P 500 inclusion.
Innovative Aerosystems, Inc. (ISSC) reported strong fiscal Q3 2026 results with revenue growth and margin expansion, while StandardAero, Inc. (SARO) delivered steady but more modest revenue increases in recent quarters. ISSC stock has shown notable upward momentum in recent weeks amid new orders and acquisitions, contrasting with SARO's more stable performance relative to broader market indices.
Upcoming earnings releases, including the next scheduled report in December 2026, could provide updates on revenue growth from commercial and military avionics demand. Strategic positioning in retrofit and original equipment manufacturer (OEM) markets for flight control systems offers medium-term expansion potential amid recovering aviation sectors.
Selected stock price target: $10 per share, approximately 50% above the recent price near $6.68. Strongest bullish factors: analyst targets clustered near or above $10, a proven ability to trade above $10 in June 2026, and treasury value tied directly to the HYPE token.
ISSC climbed 34.1% over the last 30 days, from an $18.46 close on July 17, 2026, to $24.76 intraday on August 17, 2026. The move accelerated after fiscal third-quarter results beat estimates, with adjusted EPS of $0.33 versus a $0.24 consensus.
Enovix is trading down -18.45% to $3.58 in Monday's regular session, versus Friday's close of $4.39. The primary catalyst: CEO Raj Talluri resigned effective Aug. 13; CFO Ryan Benton was named interim CEO and Chairman T.J. Rodgers became executive chairman.